| scholarly article | Q13442814 |
| P50 | author | Patricia Steeg | Q81240009 |
| P2093 | author name string | Diane Palmieri | |
| Lionel Feigenbaum | |||
| Maria J Merino | |||
| Stephen D Rubin | |||
| David J Liewehr | |||
| Seth M Steinberg | |||
| Brunilde Gril | |||
| Julie L Bronder | |||
| Eleazar Vega-Valle | |||
| Jeanne M Herring | |||
| P2860 | cites work | Phosphotyrosine interactome of the ErbB-receptor kinase family | Q24672516 |
| Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 | ||
| Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer | Q27824847 | ||
| Lapatinib plus capecitabine for HER2-positive advanced breast cancer | Q27851403 | ||
| Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas | Q28256478 | ||
| Molecular Mechanism for a Role of SHP2 in Epidermal Growth Factor Receptor Signaling | Q28609932 | ||
| The role of individual SH2 domains in mediating association of phospholipase C-gamma1 with the activated EGF receptor | Q28678514 | ||
| Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer | Q29616112 | ||
| ERBB receptors and cancer: the complexity of targeted inhibitors | Q29619520 | ||
| Involvement of pp60c-src with two major signaling pathways in human breast cancer | Q30194582 | ||
| Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain | Q33283845 | ||
| Prophylactic cranial irradiation in extensive small-cell lung cancer | Q34005742 | ||
| Breast cancer metastasis to the central nervous system | Q34455205 | ||
| Effect of a farnesyl transferase inhibitor (R115777) on ductal carcinoma in situ of the breast in a human xenograft model and on breast and ovarian cancer cell growth in vitro and in vivo. | Q35012724 | ||
| The rationale for adjuvant whole brain radiation therapy with radiosurgery in the treatment of single brain metastases | Q35101592 | ||
| Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. | Q35842144 | ||
| CNS metastases in breast cancer | Q35874807 | ||
| Stereotactic radiosurgery with and without whole-brain radiotherapy for newly diagnosed brain metastases | Q36198603 | ||
| EGFR activity in HER-2 over-expressing metastatic breast cancer: evidence for simultaneous phosphorylation of Her-2/neu and EGFR. | Q38323724 | ||
| Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines | Q40106465 | ||
| Controlled activation of ErbB1/ErbB2 heterodimers promote invasion of three-dimensional organized epithelia in an ErbB1-dependent manner: implications for progression of ErbB2-overexpressing tumors | Q40278717 | ||
| Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells | Q40321992 | ||
| The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. | Q40685410 | ||
| A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro | Q40786964 | ||
| Radiosurgery for brain metastases: is whole brain radiotherapy necessary? | Q41613693 | ||
| Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. | Q42500361 | ||
| Predominance of the basal type and HER-2/neu type in brain metastasis from breast cancer | Q42513522 | ||
| Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). | Q43846885 | ||
| Brain metastases from breast cancer: identification of a high-risk group | Q45039876 | ||
| Predictors of central nervous system metastasis in patients with metastatic breast cancer. A competing risk analysis of 579 patients treated with epirubicin-based chemotherapy | Q46542581 | ||
| Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma | Q48291216 | ||
| Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer | Q48371008 | ||
| Primary breast cancer phenotypes associated with propensity for central nervous system metastases | Q48476825 | ||
| Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. | Q52608450 | ||
| Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival | Q73644039 | ||
| Trastuzumab in CSF | Q73829301 | ||
| Correction: Meningeal carcinomatosis from breast carcinoma responsive to trastuzumab | Q74619184 | ||
| Central nervous system progression among patients with metastatic breast cancer responding to trastuzumab treatment | Q75344757 | ||
| Epidermal growth factor receptor status in breast cancer metastases to the central nervous system. Comparison with HER-2/neu status | Q80504155 | ||
| Risk factors for brain relapse in patients with metastatic breast cancer | Q80945449 | ||
| Central nervous system metastases in women after multimodality therapy for high risk breast cancer | Q81170025 | ||
| Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients | Q81414756 | ||
| P433 | issue | 15 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | metastatic breast cancer | Q12859063 |
| P304 | page(s) | 1092-1103 | |
| P577 | publication date | 2008-07-29 | |
| P1433 | published in | Journal of the National Cancer Institute | Q400279 |
| P1476 | title | Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain | |
| P478 | volume | 100 |
| Q34308176 | A novel multifunctional nanocomposite C225-conjugated Fe3O4/Ag enhances the sensitivity of nasopharyngeal carcinoma cells to radiotherapy |
| Q39320080 | A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases |
| Q48363253 | A phase II study of lapatinib for brain metastases in patients with HER2-overexpressing breast cancer following trastuzumab based systemic therapy and cranial radiotherapy: subset analysis of Japanese patients |
| Q55191633 | Activation of Neuregulin 1/ErbB Signaling Is Involved in the Development of TOCP-Induced Delayed Neuropathy. |
| Q39825225 | An in vitro study, evaluating the effect of sunitinib and/or lapatinib on two glioma cell lines |
| Q24651212 | Analyses of resected human brain metastases of breast cancer reveal the association between up-regulation of hexokinase 2 and poor prognosis |
| Q39421577 | Bay846, a new irreversible small molecule inhibitor of EGFR and Her2, is highly effective against malignant brain tumor models |
| Q37947902 | Beyond trastuzumab: new treatment options for HER2-positive breast cancer |
| Q44625585 | Biological subtypes and survival outcomes in breast cancer patients with brain metastases (study of the Anatolian Society of Medical Oncology). |
| Q37862581 | Brain metastases as preventive and therapeutic targets |
| Q36287951 | Brain metastases in Asian HER2-positive breast cancer patients: anti-HER2 treatments and their impact on survival |
| Q51193862 | Brain metastases research 1990-2010: pattern of citation and systematic review of highly cited articles. |
| Q26751008 | Brain metastasis in human epidermal growth factor receptor 2-positive breast cancer: from biology to treatment |
| Q37698300 | Breast cancer brain metastases: a review of the literature and a current multidisciplinary management guideline. |
| Q37218214 | Breast cancer metastasis: issues for the personalization of its prevention and treatment |
| Q83457870 | Breast tumor progression induced by loss of BTG2 expression is inhibited by targeted therapy with the ErbB/HER inhibitor lapatinib |
| Q38168168 | CNS metastases in breast cancer: old challenge, new frontiers |
| Q38230553 | Chemotherapy and biological treatment options in breast cancer patients with brain metastasis: an update |
| Q54654985 | Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. |
| Q47793228 | Clinical outcomes in patients who received lapatinib plus capecitabine combination therapy for HER2-positive breast cancer with brain metastasis and a comparison of survival with those who received trastuzumab-based therapy: a study by the Anatolian |
| Q34354224 | Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea. |
| Q37873453 | Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines. |
| Q47205132 | Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. |
| Q99241337 | Combination of carbon-ion beam and dual tyrosine kinase inhibitor, lapatinib, effectively destroys HER2 positive breast cancer stem-like cells |
| Q35742383 | Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer |
| Q38036217 | Combining stereotactic radiosurgery and systemic therapy for brain metastases: a potential role for temozolomide |
| Q37459640 | Comparative impact of trastuzumab and cyclophosphamide on HER-2-positive human breast cancer xenografts |
| Q42821827 | Complete Response of Brain Metastases from Breast Cancer Overexpressing HER-2/neu to Radiation and Concurrent Lapatinib and Capecitabine |
| Q38339549 | Control of EVI-1 oncogene expression in metastatic breast cancer cells through microRNA miR-22. |
| Q35705221 | Correlation between quantitative HER-2 protein expression and risk for brain metastases in HER-2+ advanced breast cancer patients receiving trastuzumab-containing therapy |
| Q28477182 | Differential impact of EGFR-targeted therapies on hypoxia responses: implications for treatment sensitivity in triple-negative metastatic breast cancer |
| Q99418051 | Dual blockade of CD47 and HER2 eliminates radioresistant breast cancer cells |
| Q36733618 | EGFR and HER2 signaling in breast cancer brain metastasis |
| Q47629685 | Effects of FSTL1 on cell proliferation in breast cancer cell line MDA‑MB‑231 and its brain metastatic variant MDA‑MB‑231‑BR. |
| Q36250585 | Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidence |
| Q89544565 | Emerging findings into molecular mechanism of brain metastasis |
| Q35075446 | Emerging strategies for treating brain metastases from breast cancer |
| Q35011982 | Enhanced antitumor effects of the BRBP1 compound peptide BRBP1-TAT-KLA on human brain metastatic breast cancer. |
| Q33924093 | Epidermal growth factor-induced heparanase nucleolar localization augments DNA topoisomerase I activity in brain metastatic breast cancer |
| Q30474678 | ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma |
| Q86891682 | ErbB2 Pathway Activation upon Smad4 Loss Promotes Lung Tumor Growth and Metastasis |
| Q36734590 | Estrogen promotes the brain metastatic colonization of triple negative breast cancer cells via an astrocyte-mediated paracrine mechanism |
| Q24296333 | FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice |
| Q38735527 | HER2 and EGFR Overexpression Support Metastatic Progression of Prostate Cancer to Bone. |
| Q37303196 | HER2 breast cancer therapies: a review |
| Q92353588 | HER2 joins AKT to inhibit STING immunity |
| Q38301236 | HER2-family signalling mechanisms, clinical implications and targeting in breast cancer |
| Q98938406 | HER2-positive breast cancer brain metastasis: A new and exciting landscape |
| Q34942996 | HER2/ErbB2 receptor signaling in rat and human prolactinoma cells: strategy for targeted prolactinoma therapy. |
| Q35023917 | Heparanase mediates a novel mechanism in lapatinib-resistant brain metastatic breast cancer |
| Q34393640 | Heterogeneous Blood–Tumor Barrier Permeability Determines Drug Efficacy in Experimental Brain Metastases of Breast Cancer |
| Q33728605 | Impact of metronomic UFT/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma |
| Q39580432 | Impact of protein tyrosine kinase 6 (PTK6) on human epidermal growth factor receptor (HER) signalling in breast cancer. |
| Q43453953 | Impacts of HER2-overexpression and molecular targeting therapy on the efficacy of stereotactic radiosurgery for brain metastases from breast cancer |
| Q36590195 | Innovative therapeutic strategies in the treatment of brain metastases |
| Q39363169 | Involvement of epidermal growth factor receptor overexpression in the promotion of breast cancer brain metastasis. |
| Q36440625 | Is the Improved Efficacy of Trastuzumab and Lapatinib Combination Worth the Added Toxicity? A Discussion of Current Evidence, Recommendations, and Ethical Issues Regarding Dual HER2-Targeted Therapy |
| Q51134329 | Kinase Inhibitor 4 Minisymposium summary. |
| Q56355750 | LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases |
| Q37782086 | Lapatinib and breast cancer: current indications and outlook for the future |
| Q36371783 | Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer. |
| Q34016491 | Lapatinib for the treatment of breast cancer in the People's Republic of China |
| Q34291564 | Lapatinib in combination with radiation diminishes tumor regrowth in HER2+ and basal-like/EGFR+ breast tumor xenografts |
| Q37376191 | Lapatinib-loaded human serum albumin nanoparticles for the prevention and treatment of triple-negative breast cancer metastasis to the brain |
| Q37605777 | Lapatinib: a review of its use in the treatment of HER2-overexpressing, trastuzumab-refractory, advanced or metastatic breast cancer |
| Q38992588 | Lapatinib: an oral dual tyrosine kinase inhibitor for HER-2-positive breast cancer |
| Q37771017 | Lapatinib: in postmenopausal women with hormone receptor-positive, HER2-positive metastatic breast cancer |
| Q38794850 | MRI surveillance of cancer cell fate in a brain metastasis model after early radiotherapy |
| Q34241118 | Management of ErbB2-positive breast cancer: insights from preclinical and clinical studies with lapatinib |
| Q26865562 | Management of solitary and multiple brain metastases from breast cancer |
| Q38269966 | Meaningful prevention of breast cancer metastasis: candidate therapeutics, preclinical validation, and clinical trial concerns |
| Q34134390 | Metabolism considerations for kinase inhibitors in cancer treatment |
| Q30437720 | Metastasis Research Society-American Association For Cancer Research Joint Conference on Metastasis. |
| Q36761252 | Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth |
| Q35909895 | Molecular aspects of breast cancer metastasis to the brain |
| Q27345217 | Monitoring the systemic human memory B cell compartment of melanoma patients for anti-tumor IgG antibodies |
| Q35966786 | Mouse models of advanced spontaneous metastasis for experimental therapeutics |
| Q37244367 | Nearly Complete Response of Brain Metastases from HER2 Overexpressing Breast Cancer with Lapatinib and Capecitabine after Whole Brain Irradiation |
| Q35119038 | Notch1 inhibition alters the CD44hi/CD24lo population and reduces the formation of brain metastases from breast cancer. |
| Q37523202 | Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. |
| Q37790962 | Novel insights into the management of brain metastases |
| Q38631975 | Oral Targeted Therapies and Central Nervous System (CNS) Metastases |
| Q35828652 | Organ-specific adaptive signaling pathway activation in metastatic breast cancer cells |
| Q27006181 | PI3K pathway inhibitors for the treatment of brain metastases with a focus on HER2+ breast cancer |
| Q38281325 | Pathogenesis of Breast Cancer Metastasis to Brain: a Comprehensive Approach to the Signaling Network |
| Q34690325 | Pazopanib Reveals a Role for Tumor Cell B-Raf in the Prevention of HER2+ Breast Cancer Brain Metastasis |
| Q36888327 | Pazopanib inhibits the activation of PDGFRβ-expressing astrocytes in the brain metastatic microenvironment of breast cancer cells |
| Q34268838 | Pharmacologic inhibition of MLK3 kinase activity blocks the in vitro migratory capacity of breast cancer cells but has no effect on breast cancer brain metastasis in a mouse xenograft model |
| Q36514775 | Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimen |
| Q44179284 | Phase II, open-label trial of lapatinib and vinorelbine in women with previously treated HER2-positive metastatic breast cancer |
| Q37498669 | Physiologically based pharmacokinetic model of lapatinib developed in mice and scaled to humans |
| Q35051651 | Preclinical antitumor activity of S-222611, an oral reversible tyrosine kinase inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2 |
| Q35967411 | Preclinical approaches to study the biology and treatment of brain metastases |
| Q35159916 | Predicting early brain metastases based on clinicopathological factors and gene expression analysis in advanced HER2-positive breast cancer patients. |
| Q33909294 | Profound prevention of experimental brain metastases of breast cancer by temozolomide in an MGMT-dependent manner |
| Q33901255 | Protein pathway activation mapping of brain metastasis from lung and breast cancers reveals organ type specific drug target activation |
| Q36040355 | Proteotranscriptomic Profiling of 231-BR Breast Cancer Cells: Identification of Potential Biomarkers and Therapeutic Targets for Brain Metastasis |
| Q37694756 | Radiosensitizing effect of lapatinib in human epidermal growth factor receptor 2-positive breast cancer cells |
| Q49123747 | Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases |
| Q37185154 | Reactive glia are recruited by highly proliferative brain metastases of breast cancer and promote tumor cell colonization |
| Q37904792 | Revisiting the role of molecular targeted therapies in patients with brain metastases. |
| Q37355762 | Role of lapatinib alone or in combination in the treatment of HER2-positive breast cancer |
| Q34417920 | Role of lapatinib in the first-line treatment of patients with metastatic breast cancer. |
| Q37462623 | SMURF1 plays a role in EGF-induced breast cancer cell migration and invasion. |
| Q37193756 | SRC family kinases as novel therapeutic targets to treat breast cancer brain metastases. |
| Q33519056 | Secreted Gaussia luciferase as a biomarker for monitoring tumor progression and treatment response of systemic metastases |
| Q35832897 | Stat3 orchestrates interaction between endothelial and tumor cells and inhibition of Stat3 suppresses brain metastasis of breast cancer cells |
| Q38285931 | Systemic therapy of brain metastases. |
| Q39652258 | Systemic treatment of brain metastases in HER2-positive breast cancer: current status and future directions |
| Q39005489 | TPI-287, a new taxane family member, reduces the brain metastatic colonization of breast cancer cells |
| Q39147161 | Targeted Therapies in HER2-Overexpressing Metastatic Breast Cancer |
| Q90862850 | Targeted therapeutic options and future perspectives for HER2-positive breast cancer |
| Q37053185 | Targeting αV-integrins decreased metastasis and increased survival in a nude rat breast cancer brain metastasis model |
| Q35676602 | The biology of brain metastases-translation to new therapies |
| Q39577741 | The effect of mTOR inhibition alone or combined with MEK inhibitors on brain metastasis: an in vivo analysis in triple-negative breast cancer models |
| Q37304764 | The potential role of nanotechnology in therapeutic approaches for triple negative breast cancer |
| Q34503022 | The role of MMP-1 in breast cancer growth and metastasis to the brain in a xenograft model |
| Q34268618 | Therapeutic Considerations in Treating HER2-Positive Metastatic Breast Cancer |
| Q37809862 | Therapy and prophylaxis of brain metastases |
| Q34052760 | Toward a drug development path that targets metastatic progression in osteosarcoma. |
| Q33805406 | Translational research in brain metastasis is identifying molecular pathways that may lead to the development of new therapeutic strategies |
| Q33867316 | Trastuzumab uptake and its relation to efficacy in an animal model of HER2-positive breast cancer brain metastasis |
| Q33747400 | Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases--the UK experience. |
| Q30458767 | Treatment of vestibular schwannoma cells with ErbB inhibitors |
| Q35804288 | Understanding Heterogeneity and Permeability of Brain Metastases in Murine Models of HER2-Positive Breast Cancer Through Magnetic Resonance Imaging: Implications for Detection and Therapy |
| Q39793584 | Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks |
| Q38778447 | miR-141-Mediated Regulation of Brain Metastasis From Breast Cancer. |
Search more.